What it's for (Indications)
- This medication, a combination of salbutamol (albuterol) and guaifenesin, is indicated for the symptomatic relief of bronchospasm associated with acute or chronic reversible obstructive airway diseases, such as bronchial asthma, asthmatic bronchitis, chronic bronchitis, and emphysema, where both bronchodilation and an expectorant action are considered beneficial.
- Salbutamol acts as a bronchodilator to relax airway muscles and improve breathing, while guaifenesin helps to thin and loosen mucus in the lungs, making it easier to cough up.
- This combined action aims to alleviate respiratory distress and improve mucociliary clearance in patients experiencing both bronchoconstriction and tenacious sputum production.
- It is specifically designed for situations where a productive cough is present alongside airway narrowing.
- The precise diagnosis and suitability for this combination therapy should always be determined by a qualified healthcare professional, as its use is targeted at specific pathological presentations of respiratory conditions.
- Careful patient selection is crucial to ensure optimal therapeutic outcomes and minimize potential risks, particularly in pediatric and elderly populations who may have altered pharmacokinetic profiles or comorbid conditions influencing drug response.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage for the salbutamol and guaifenesin combination syrup must be individualized based on the patient's age, weight, medical condition, and response to treatment. For adults and children 12 years of age and older, a typical recommended dose might be 5 mL to 10 mL (containing appropriate doses of salbutamol and guaifenesin as per specific product formulation) taken orally three to four times daily. For children aged 6 to 12 years, the dosage is usually adjusted based on body weight, often around 2.5 mL to 5 mL three to four times daily, with strict adherence to manufacturer guidelines and pediatric dosing charts. For children under 6 years, use is generally not recommended unless specifically prescribed and monitored by a pediatrician due to potential risks and varying metabolic rates. Dosing should not exceed the maximum daily allowance to prevent accumulation and adverse effects. It is imperative to use an accurate measuring device (e.g., an oral syringe or measuring spoon) to ensure precise dosing and avoid errors. Patients should be advised not to exceed the prescribed dose or frequency, as doing so may increase the risk of adverse cardiovascular effects and other systemic reactions associated with beta-adrenergic stimulation. Always consult a healthcare professional for specific dosing instructions and adjustments, and never self-medicate or alter prescribed doses. |
Safety & Warnings
Common Side Effects
- Common side effects associated with the salbutamol and guaifenesin combination largely stem from the beta-adrenergic activity of salbutamol.
- These frequently include tremor, nervousness, dizziness, headache, palpitations, and tachycardia.
- Patients may also experience muscle cramps, hyperactivity (especially in children), and insomnia.
- Gastrointestinal disturbances such as nausea, vomiting, and stomach upset are possible, particularly from the guaifenesin component, though typically mild.
- Less common but more severe side effects that warrant immediate medical attention include paradoxical bronchospasm (worsening of breathing difficulty after administration), angioedema, urticaria, rash, hypotension, hypertension, and serious cardiac arrhythmias.
- Hypokalemia, although often transient and not requiring supplementation, can occur with high doses.
- Patients with pre-existing cardiovascular conditions, diabetes, or hyperthyroidism may be more susceptible to these adverse effects.
- Any new or worsening symptoms, particularly respiratory distress, chest pain, or severe dizziness, should prompt immediate discontinuation of the medication and consultation with a healthcare provider.
- The incidence and severity of side effects are often dose-dependent, emphasizing the importance of adherence to prescribed dosages.
Serious Warnings
- Black Box Warning: While there is no formal FDA-issued 'Black Box Warning' specifically for the combination of salbutamol and guaifenesin, it is crucial to highlight several 'Serious Warnings' that demand vigilant attention from both patients and healthcare providers. The salbutamol component, a short-acting beta-agonist (SABA), can lead to significant cardiovascular effects, including serious arrhythmias, tachycardia, and blood pressure changes, especially in susceptible individuals or with excessive use. Patients with pre-existing cardiovascular disease are at increased risk. There is also a risk of paradoxical bronchospasm, an acute life-threatening worsening of breathing immediately after administration; if this occurs, the medication must be discontinued immediately, and alternative therapy instituted. Over-reliance on SABAs for symptom control may mask worsening asthma and can indicate inadequate underlying disease management, potentially increasing the risk of severe asthma exacerbations. Patients should be explicitly educated on proper use and the dangers of exceeding prescribed doses. Guaifenesin's expectorant action should not be misconstrued as a cure for chronic cough, which may signal more serious underlying conditions requiring different diagnostic and therapeutic interventions. Continued use without medical supervision for a persistent cough is not recommended. Healthcare professionals must ensure patients understand that this medication is for symptomatic relief and not a substitute for controller medications in asthma management.
- This combination medication should be used with extreme caution in patients with cardiovascular disorders, including coronary insufficiency, cardiac arrhythmias, and hypertension, as salbutamol can cause transient increases in heart rate and blood pressure, potentially exacerbating these conditions.
- Patients with a history of seizures, hyperthyroidism, or diabetes mellitus should also be closely monitored, as salbutamol can worsen glycemic control and thyroid function.
- Paradoxical bronchospasm, characterized by an acute worsening of breathlessness immediately after administration, can occur; if this happens, the medication should be discontinued immediately, and an alternative therapy should be considered.
- Guaifenesin may cause drowsiness, and patients should be cautioned about operating machinery or driving until they know how the medication affects them.
- The use of this product for chronic cough, such as that occurring with smoking, asthma (unless specifically for bronchospasm and mucus), or emphysema, is generally not recommended without a physician's advice.
- Patients should be advised to seek medical attention if their cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or persistent headache, as these could be signs of a more serious underlying condition requiring different treatment.
- Concomitant use with other sympathomimetic agents or MAOIs should be avoided or closely supervised due to additive cardiovascular effects.
- The safety and efficacy of this combination in pregnant or breastfeeding women have not been definitively established, requiring a careful risk-benefit assessment.
How it Works (Mechanism of Action)
The therapeutic action of this combination medication is attributed to the synergistic effects of its two active components: salbutamol and guaifenesin. Salbutamol, a short-acting beta-2 adrenergic agonist (SABA), exerts its primary effect by selectively stimulating beta-2 adrenergic receptors located in the smooth muscle cells of the bronchial tree. This stimulation leads to the activation of adenyl cyclase, which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Increased intracellular levels of cAMP result in the relaxation of bronchial smooth muscle, thereby causing bronchodilation and relieving airway obstruction. This action also inhibits the release of mast cell mediators. Guaifenesin functions as an expectorant, working to reduce the viscosity and adhesiveness of tenacious mucus in the respiratory tract. It is believed to achieve this by irritating the gastric mucosa, which reflexively increases the volume and reduces the stickiness of respiratory tract secretions. This improved fluidity of bronchial secretions facilitates easier removal of mucus through ciliary action and coughing, thereby helping to clear the airways and improve pulmonary function. The combined effect of bronchodilation and enhanced mucociliary clearance aims to provide comprehensive symptomatic relief for patients experiencing both airway constriction and excessive, thick mucus production.
Commercial Brands (Alternatives)
No other brands found for this formula.